How CareDx Is Bringing AI to Transplant Care

Brisbane, CA-based CareDx has partnered with Cibiltech, a French company that develops artificial intelligence-based products for predictive medicine, to commercialize Predigraft.  Predigraft is a data analysis tool designed to provide an early prediction of a patient's risk of allograft rejection and transplant loss. It was developed from Cibiltech’s software algorithm called iBox, which is built off the outcomes data from tens of thousands of transplant patients. The deal is yet another example of how AI is disrupting the status quo in medtech. MD+DI recently published this guide characterizing the current state of AI in the industry from technical considerations to regulatory and reimbursement challenges. CareDx now has the exclusive rights to sell Predigraft in the United States. The company also acquired a minority equity ownership of Cibiltech. The companies have also agreed to collaborate to advance the development of AI in transplant care. Financial terms of the deal were not disclosed.  The news comes on the heels of the company's recent $16 million acquisition of OTTR Complete Transplant Management, a provider of organ transplant patient tracking software. That deal is expected to close this month. "We're moving from proprietary biomarkers to multimodality testing and then we're adding to this multimodality testing our artificial intelligence component to make sure there's digital healthcare available...
Source: MDDI - Category: Medical Devices Authors: Tags: Software Source Type: news